Grifols partners with IBL to develop advanced biomarker panels for a clinical diagnostics platform
Grifols se asocia con IBL para el desarrollo de paneles de biomarcadores avanzados para una plataforma de diagnóstico clínico
Intel ID : 413494
Relevant Documents
| Press Release | 08 Apr 2025 | Grifols_Nota_de_Prensa_2025.pdf | ES |
|
| Intel ID | 413494 | |||
| Value | ND | |||
| Native Currency | Euro (EUR) | |||
|
Financial Data - Grifols
(31 Dec 2023) |
Revenue: EUR 7.077,97m EBITDA: EUR 1.247,56m Net Debt: EUR 10.541,45m |
|||
| Date |
 |
|||
| Country |  |
|||
| Geography | |
|||
| Subsector (Old TTR Sectors) |
|
|||
| Primary Subsector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|||
| Type |
|
|||
| Intel Grade |
|
|||
| Source |
|
|||
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.